{"id":835869,"date":"2025-04-10T02:03:06","date_gmt":"2025-04-10T06:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/"},"modified":"2025-04-10T02:03:06","modified_gmt":"2025-04-10T06:03:06","slug":"maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/","title":{"rendered":"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ROCKVILLE, Md., April  10, 2025  (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.<\/p>\n<p>\n        <strong>Earnings Conference Call Details<\/strong><br \/>\n        <br \/>Investors interested in listening to the conference call are required to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X8fzcsAFEe8P9olAYwOAW9YM375yXWALimwL-2cGTqmz37dBSGPfcXQ8ER3engSNL3jZPrTTIsuhCD2Xb1IJt8iWzS6jWHzXTNMBPVzQw3hJ3M7-FRmczW5mMVATlz8sdEHvD92U1zAzVUQsN_2Jf1KEJ77QM4Z09Ld7vL0K5Ws=\" rel=\"nofollow\" target=\"_blank\">register online<\/a>. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of the MaxCyte website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SMiWlQspFVi0otOUE_ADQX7SuuPU6BIRbTb0vezjnK2NZmIZDtYKrRf9gQ-MQIorAIN0TKthyuIcqeZDfjsn4AKumes6ou2lQD2bG2ZPiCwlhM8anAyq-XIhEktGx1_b\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.maxcyte.com\/<\/a>.<\/p>\n<p>\n        <strong>About MaxCyte<\/strong>\n      <\/p>\n<p align=\"justify\">At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients\u2019 lives. We have spent more than 25 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today\u2019s processes to innovate tomorrow\u2019s solutions. Our ExPERT\u2122 platform, which is based on our Flow Electroporation<sup><em>\u00ae<\/em><\/sup>\u00a0technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx\u2122, STx\u2122, GTx\u2122 and VLx \u2122; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2bifjpVlr6W8OadblAAZJ94Tl3MctS2LNnSbNASZSSgLQxhwqYU6UbbHERT0lI00tKBCMbicDWOidftokSeWASDUOGNBBTjaFgZH-1zzSHcZM1MnWmFJyOJ7NIK93qEOJ6axF2FHJ58BDfQhE_s1z0LQ15MqSq5Q9PJsEYfj1jvpw1C4Nwmc41VVQ1n2V_7TBXrK9mAAK0t4t73SudMrQUsIWmHTv1m4fobCD2CqWW5nIqaQ_cgpktzAfglRZ1AqoJYVnWqDDUH0eMUGGO-3QaQQv91ZbBcj8IWffk8kIOfCsayW3k55wztpaVESF1-bb84qJEDfm6vZDvxA0cXVffFS8Jlz6Arc5yZCkeYJdKbZt6DQsnjjPVJ87KYznAMEjzaXYNo0NiIWor4AL17XAEzbhNNOXjnSmRKrjwR2ITv6KQY1IMDgTcVOjdv_2mekTTe263DBh5ZQinE8QVT9aKSoxW5fVQvbzUwu7-1hIFyD52XoLgCaZi8Zi6KEIVAPa5w_4Co9CpZTUUEoxMgqWdyzlw2wMBFcekA-rmoBCZOyglPhBQC4CfhHByXvBbBRRmAfXo-Ba3u_goqdvChzPt4GTSNRPtSe5Mjsx5taN0XBqQM9N3V95Kh7RC3DqClIvJIMC9tmODncBIQPQFdnhkgUZMAkJ5LgGtx3yYj8LV_qAAzF9fpdDNYc5F8927jHYCtVQOYSFREDEDF8sVDcipWxv4Zl1giwVpNfniFR3vlwAte08CHKCDYMZZ0cA5dcpt5C7JKCNVr1OnUs5s1xQohkKsjBquQYSsWAbzK6Ro8rDPWn4qG8cUOQ5h4-zGRBZqXlYuRISdXZuzAn3KXK092quXKGKykufyY3hFYzSlHZzoECA8wJHbJ1d8H1ul9Ysh07tXQySdMx5ToDS-nwsw==\" rel=\"nofollow\" target=\"_blank\">maxcyte.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-oSQncdcpSEWCjPCqke59yklrNeSyRmWzG6hI3NHHiBrIJXA4q4m27hMBQLIf5PUbkPWhIR2HIXsQavK2n5FwmnhKQla1d2GfUbd4X2-rowMPs14sapgUprJBq3yOrK-qP9AVnxGEtIW1DBS4qOb_TVpOdhASbKtxNlLm21vDCx9tkq-MUXti0MtNU2MzkAi3hkEuctBooVwGDnCxkrk6OxUB8OPIKgcdzv4z2RdKlNZE09i33JcTds18NY8UI_8QeSdTcwblfWeWYXUHau8XW3oDBGJOA2TLDSwbQSXKbE_oU4j3hJ2sxu23AK1Eh6FlU-uB4fQLbMK4n1ty_bIhpSuFhH2qr0DoEq7KlR3nvGilVHw_9u-Ud7-TYjpHATIgcY0fi6E-W6xKoGqnitI2jrdhbb6RZ1Roz4_qSxNjqkGQfToJjUvEdwS0fhK0FZyjuBkHIE5rCFv87iZXMxo8i3UnOPdrZujJZJS2gcyYsKuIXeIVzf2l5rRlUBWagOT9ysp80C_wMZLM41U0GeHTFQ4rRJTgDyd9vSXImBZjSqNXg4Jdb62SQbva53bsVm-Fl4qJcMMtq6bFCropFJpJN2mDXJv__ASat5oCe5X25Eudx0DXK9HnTrc6i4nrDG5sseKBL-IkJEgZBxJhpwtaRK6jkub_1DyHtzMd9u06leiUUeYBhaLKZ_sC64ifqwzTY6KOPSJP3N_fjGIcxH3HiJ4sKjj9Wj4B39_3jcoUK6HLr8znLuqDjuPLvz5SY1pcN-Uz7l__KDyszVf3GQoVCpbQn_39_H1VCOR5JNCbnCNnwKglcBvlhxSkQPaa1Hp_AgaFE_goSGeRZuiTSc6hltZ1wRsPUgdQLrktsoPeiG8DLZVC7UL0q_XzeDutJGFWlzDUfZzp5UBDucFDO99Bw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dr8H0fZUf5memJL8f44JJGSgaHCQ8cy_604OK-R38kHECXXKPtOoy8yGaLHHNVq6jdP6gj8Sfb11xOIMAS4wzHgEQj3SMuc6lH8ThIJgQJp4SSSfWRovIZzXXdmJRFuJtwUj6c8FxYdAp8f2NWCFad-1Rj1u9CXLdMVfd0LzNFI7tjk-DjdumGPLGNggqifwbrS55X5GecJzgEqg55PJAa8tlTQFNbO99O704jK6OPJnUmkgww4YT5LwXCPKDFyXdSUmGFzLJ28bFSLrlQ4-AZfd61etDzxSCDHi6frvdus4BuDU2D7pDC5xVo0VFAiVPe4IG2rlMfFd8AI3SsSxTDY69zP0NSSNngLo7zdo3WTsh2UJesx7B3qMNXU_sW5ATZBWXJrd2mbTDn_IKGN3M0SixBA5toadi98bsOws5aMKZAdj-slyqX2PzVMWrkMZM0koTAKAflPFVXAK9OS8Vbx915_vH8JpZxkmnUjFpr4Ub2TffKy8MtGfBsCrBIe3O3to9kPjdZ7aEJ14epd5RD_0VyQe_0rAR1Nqgi689Snc7ToMyxylgZj-3dJE1Zm4zg2OM8wQG6JG-DlXDeF1VzVQF0R299fYY92uJJ-FrBFxPHnQt8dWLlqHrSp5PbjbboFHAYnZd6iw7S-PrSb7RjbJYezLlFHMFtPPEvSLTjyKs7X-M6C8CBl_AXOiL_VtSqvG3KyNOSImpptvCLjzpRE_CbGF9GVdp0CwcxlaqEMGdV-FlvWx100klzV3k2dkmV_4cLolFauVxMpnxDHPwHHQ4_VONjhNYANdMrH8bUeIK7F1hnk4hhhvPsGSMk2nzgY6ZVe2MHckQTTHBAMe9pZetxabg7j6jg4Tcc7fg9ghRUbwdFn0FlaRwokZfz1_Fx3B7LsfMJPSdn2VLwvmszzJEh8w_9EFx-tvOkjCb59zVeOHTckciLKFbzL1qyMM\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>MaxCyte Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>US IR Adviser<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Gilmartin Group<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>David Deuchler, CFA<br \/>+1 415-937-5400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7JhJ-kcqKD9AffWA7zvwirJnn3qtadEMo_iWsfuhkZ7XF1_1gddVc4UN3g3kA-0Pl5fCYwdQzNJ0Cf5AcCQE7Q==\" rel=\"nofollow\" target=\"_blank\">ir@maxcyte.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <em>US Media Relations<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Spectrum Science<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Jordan Vines<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QyYA_rtk6xXKNN176A1vo69vfHk8LRzRbwKPVxlCeqlt2cxu3atgFMnPByhL8C38Zg8Uap23c5WDZlNp-aqopyZVAwW5HqVGJsj-hFq-Q0ACeDQAnW7F3G-tTef5pwpZ\" rel=\"nofollow\" target=\"_blank\">jvines@spectrumscience.com<\/a><br \/>+1 540-629-3137<\/p>\n<p>\n        <strong><br \/>\n          <em>Nominated Adviser and Joint Corporate Broker<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Panmure Liberum<br \/>Emma Earl \/ Freddy Crossley<br \/>Corporate Broking<br \/>Rupert Dearden<br \/>+44 (0)20 7886 2500<\/p>\n<p>\n        <strong><br \/>\n          <em>UK IR Adviser<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>ICR Healthcare<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Mary-Jane Elliott<br \/>Chris Welsh<br \/>+44 (0)203 709 5700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2bifjpVlr6W8OadblAAZJ0yc2E3Hb2H8zGUYIo4ppSknDv95bi_RgHwLq3Dkm_hO6SaSiGqBtWneQpIQyj8AdAMqN3KpFWST77lHCXNj5MW9D8fA6Q47zRYSkjOJAu2U\" rel=\"nofollow\" target=\"_blank\">maxcyte@icrhealthcare.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjdhYzE5YTUtZTZjYS00YTMyLTg4YWEtYjEzZjBlMTU4ZjIxLTEyMTY3MzEtMjAyNS0wNC0xMC1lbg==\/tiny\/MaxCyte-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of the MaxCyte website &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-835869","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of the MaxCyte website &hellip; Continue reading &quot;MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T06:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025\",\"datePublished\":\"2025-04-10T06:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/\"},\"wordCount\":353,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/\",\"name\":\"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=\",\"datePublished\":\"2025-04-10T06:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/","og_locale":"en_US","og_type":"article","og_title":"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - Market Newsdesk","og_description":"ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) &#8212; MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2025 after the U.S. market close on Wednesday, May 7th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call Details Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the \u201cEvents\u201d section of the MaxCyte website &hellip; Continue reading \"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-10T06:03:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025","datePublished":"2025-04-10T06:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/"},"wordCount":353,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/","name":"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=","datePublished":"2025-04-10T06:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxOTY3OSM2ODU4OTc3IzIyMDUxNzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/maxcyte-to-report-first-quarter-2025-financial-results-on-may-7-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=835869"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=835869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=835869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=835869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}